Sillajen Inc. has recently presented data regarding their threonine tyrosine kinase (TTK) and Polo-like kinase 1 (PLK1) dual inhibitor BAL-0891 as a therapeutic approach for acute myeloid leukemia (AML) treatment. The compound was tested both in vitro and in vivo in the preclinical setting.
An 85% remissions rate was found in updated results from Aptevo Therapeutics Inc.’s ongoing phase Ib/II Ranier study of mipletamig in one of the toughest blood cancers to treat.
“The lack of therapeutic precision in treatment of myeloid malignancies is in sharp contrast with the fact that myeloid cancers represent the perhaps best characterized cancers of all at the cellular, molecular, and genetic levels,” Johanna Olweus told her audience at the Friday plenary session of the European Hematology Association 2025 Annual Congress.
“The lack of therapeutic precision in treatment of myeloid malignancies is in sharp contrast with the fact that myeloid cancers represent the perhaps best characterized cancers of all at the cellular, molecular, and genetic levels,” Johanna Olweus told her audience at the Friday plenary session of the European Hematology Association 2025 Annual Congress.
Acute myeloid leukemia (AML) is an aggressive blood cancer characterized by the accumulation of immature myeloid cells. Current treatments often fail to achieve durable remission, underscoring the need for innovative therapeutic approaches. CD97 is a cell surface protein with broad, increased expression on AML cells compared to normal blood stem and progenitor cells. Moreover, CD97 overexpression in AML patients has been associated with poor survival, thus emerging as a potential therapeutic target.
Acute myeloid leukemia (AML) is the most prevalent hematological malignancy. Despite advances in the field, about 60% of patients with AML do not survive >5 years. It is an urgent need to identify novel therapeutic targets for managing AML.
Transition Bio Ltd. has disclosed YTH domain-containing protein 1 (YTHDC1; YT521-B) inhibitors reported to be useful for the treatment of acute myeloid leukemia (AML).
Despite the variety of treatments available for acute myeloid leukemia (AML), their therapeutic efficacy remains limited, and the 5-year survival rate is still below 30%. Epigenetic changes, including DNA methylation and histone modification, appear to play a role in AML development and progression, emerging as promising targets.
.webp?height=488&t=1670008838&width=650 "Acute myeloid leukemia")
